Jump to content

Stock Traders,,,, Idi Chudandi


Recommended Posts

Posted

ZIOP anta
Options activity baga undi,, few months lo $20 ki velle chance undi, small research chesa after hearing thru my friend

Note: meru kuda research chesi pettandi,,,, nenu emi trading cheyatam ledu,,,,just meku kuda help avudi ani cheputuna

 

Nuvvu cheyyakunda inkokadini cheyyi kaalchuko annattu undi. 

  • Replies 102
  • Created
  • Last Reply

Top Posters In This Topic

  • always_happy116

    22

  • Hyderabad_Nawab

    18

  • Nidhi90

    17

  • sandie

    13

Posted

Nuvvu cheyyakunda inkokadini cheyyi kaalchuko annattu undi.


Nake money unte, guarantee ga indulo pette vadini
Atleast db valaki help avutundani cheppa,,,, valla research kuda cheyamanna
Posted

sure.. Thanks..
12.90s lo alaa konochantara?

Market Intha Kante Inka ekkuva peragadu


Oka vela perigina inkoka 1$ padathadi


Market padatam start aythe Vix double avvuthadi


Kaani market Inka peragataaniki no chances
Posted

VIX direct ga trade cheyalem kada.  VIX options cheyachu. u mean VXX ?

Posted

Market Intha Kante Inka ekkuva peragadu


Oka vela perigina inkoka 1$ padathadi


Market padatam start aythe Vix double avvuthadi


Kaani market Inka peragataaniki no chances

Vix Endi mayya sa.gif
Posted

3 days before I did a CALL SAM. At sp 290$

I closed day before yesterday.

Then I entered yesterday

Changed strategy


PUT at 300$


Closed today @ 258$


Neenu 260 put konali anukunna kani work lo padi marchipoya...next week ssys call konte konochu...
Posted

ZIOP anta
Options activity baga undi,, few months lo $20 ki velle chance undi, small research chesa after hearing thru my friend

Note: meru kuda research chesi pettandi,,,, nenu emi trading cheyatam ledu,,,,just meku kuda help avudi ani cheputuna

 

:3D_Smiles_38: :3D_Smiles_38: :3D_Smiles_38:  ZIOP: $13

 

 

inka em anna suggest cheyyi thelsithe...
 

  • 2 weeks later...
Posted
ZIOPHARM Oncology (ZIOP) Downgraded From Hold to Sell
 
By TheStreet Quant Ratings Follow | 03/11/15 - 03:00 PM EDT
SpeedDesk-19-large.jpg

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet, Inc., or any of its contributors.  TheStreet Ratings quantitative algorithm evaluates over 4,300 stocks on a daily basis by 32 different data factors and assigns a unique buy, sell, or hold recommendation on each stock.  Click here to learn more.

NEW YORK (TheStreet) -- ZIOPHARM Oncology  (ZIOP - Get Report) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D-.  TheStreet Ratings Team has this to say about their recommendation:

"We rate ZIOPHARM ONCOLOGY INC (ZIOP) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has decreased by 16.8% when compared to the same quarter one year ago, dropping from -$8.90 million to -$10.40 million.
  • Net operating cash flow has declined marginally to -$9.87 million or 9.12% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • ZIOPHARM ONCOLOGY INC's earnings per share declined by 11.1% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ZIOPHARM ONCOLOGY INC continued to lose money by earning -$0.32 versus -$0.66 in the prior year. For the next year, the market is expecting a contraction of 60.9% in earnings (-$0.52 versus -$0.32).
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ZIOPHARM ONCOLOGY INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ZIOP has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.97, which clearly demonstrates the ability to cover short-term cash needs.
  • You can view the full analysis from the report here: ZIOP Ratings Report
Posted

Ida ZIOP evaru konale.. U May Go Now...Panikocche Konni Stocks seffi po Pls.. .rlxuhc_th.jpg

Posted

Ida ZIOP evaru konale.. U May Go Now...Panikocche Konni Stocks seffi po Pls.. .rlxuhc_th.jpg


Konachaaa nuvvu
Posted

Konachaaa nuvvu

Nope.. pakka oka 50C anna vacche stocks seffu maa.. No Opika to so called Research.. oka 1000 koni 500$ profit tho potha EOD.. rlxuhc_th.jpg

Posted

Nope.. pakka oka 50C anna vacche stocks seffu maa.. No Opika to so called Research.. oka 1000 koni 500$ profit tho potha EOD.. rlxuhc_th.jpg


SUNE VIPS pandagane chesuko.. profit lo naku share ivvu..
Posted

Ida ZIOP evaru konale.. U May Go Now...Panikocche Konni Stocks seffi po Pls.. .rlxuhc_th.jpg

 

 

Hottest Healthcare Stocks Now – MACK ZIOP ALNY BMRN ACHN leads healthcare stocks lower on Thursday
By Portfolio Grader  |  Mar 5, 2015, 11:45 am EDT

Healthcare stocks rose 0.7% on Wall Street on Thursday morning.

More broadly, the Dow Jones Industrial Average was up 0.1%, the Nasdaq climbed 0.3% and the S&P 500 pushed 0.1% higher.

Some of the biggest gainers among healthcare stocks include:

  • Merrimack Pharmaceuticals Inc (MACK): MACK stock is up 5.0%, marking the third consecutive day the stock has increased.
  • Ziopharm Oncology Inc (ZIOP): ZIOP stock is up 4.9%, marking the third consecutive day the stock has increased.
  • Alnylam Pharmaceuticals (ALNY): ALNY stock is up 6.0%, marking the fourth consecutive day the stock has increased.
  • Biomarin Pharmaceutical Inc (BMRN): BMRN stock is up 4.9% today.
  • Celldex Therapeutics Inc (CLDX): CLDX stock is up 5.0% today and up 40.9% in the last month.
  • Sangamo Biosciences (SGMO): SGMO stock is up 3.2% today.
  • Bluebird Bio Inc (BLUE): BLUE stock is up 4.2%, marking the third consecutive day the stock has increased.
  • Puma Biotechnology (PBYI): PBYI stock is up 4.4% today.
  • Ariad Pharmaceuticals (ARIA): ARIA stock is up 3.8% today and up 22.1% in the last month.
  • Incyte Corp (INCY): INCY stock is up 5.3% today.

Some of the biggest losers among healthcare stocks include:

  • Achillion Pharmaceuticals (ACHN): ACHN stock is down 10.4%, marking the third consecutive day the stock has decreased.
  • Abbvie Inc. Common Stock (ABBV): ABBV stock is down 2.0% today.
  • Horizon Pharma Inc (HZNP): HZNP stock is down 2.0% today.
  • Mannkind Corp (MNKD): MNKD stock is down 3.9%, marking the third consecutive day the stock has decreased.
  • Msa Safety Inc. (MSA): MSA stock is down 2.3% today.
  • Tenet Healthcare Corp (THC): THC stock is down 2.6% today.
  • Orexigen Therapeutics (OREX): OREX stock is down 4.0% today.
  • Hca Holdings Inc. Common Stock (HCA): HCA stock is down 0.8% today.
  • Hms Holdings Corp (HMSY): HMSY stock is down 1.3%, marking the third consecutive day the stock has decreased.
  • Kindred Healthcare (KND): KND stock is down 0.5% today.
×
×
  • Create New...